EXPERIMENTAL MODELS OF DIABETES MELLITUS

Jelena Pantić1, Vladislav Volarević1, Aleksandar Đukić1

1Faculty of Medicine, University of Kragujevac

Correspondence to: Jelena Pantić, Address: Janka Veselinovica 3/3, 11000 Beograd
Tel: 064/1550001, 011/3861942, E-mail: panticjelena@open.telekom.rs

APSTRAKT

Early studies on pancreatectomised dogs confirmed the central role of the pancreas in the homeostasis of glycemia and resulted in the discovery of insulin. Today, hundreds of different animal models are used in experimental studies of diabetes. The aim of this review is to present experimental models of type 1 and type 2 diabetes. In preparing for this review, we searched the electronic databases Medline, Highwire, and Hinari.

The majority of the experiments are conducted on rodent models (mice and rats). Selective inbreeding resulted in the development of numerous models with pathogenic characteristics and the manifestation of type 1 and 2 diabetes and the related phenotypes of obesity and insulin resistance. In addition to analyzing the pathogenic mechanisms of the disease and its complications, these models are used to evaluate new treatment solutions as well as the transplantation of beta cells and disease prevention. New animal models have been created using techniques based in molecular biology and genetic engineering: transgenic, knockout and tissue-specific knockout models. These are very powerful methods, which may lead to exciting results in the future.

Key words: animal models, experimental diabetes, mouse, rat

SAŽETAK

Prve studije rađene na psima kojima je prethodno uklonjen pankreas potvrdile su centralnu ulogu pankreasa u homeostazi glikemije i doprineli otkriću insulina. Danas, veliki broj različitih eksperimentalnih modela se koristi u istraživanjima u oblasti dijabetesa. Cilj ovog revijskog rada je da predstavi neke od ovih modela, koristeći kao literaturnu originalne i revijske radove elektronskih baza Medline, Highwire i Hinari.

Većina laboratorija koristi selektivnim inbridingom dobijene miševe i pacove, kao i transgene i nokaut životinje dobijene genetskim inženjeringom, koje zbog svojih karakteristika (npr. gojaznost, rezistencija na insulin) predstavljaju idealne eksperimentalne modele za dijabetes tip 1 ili 2. Ovi eksperimentalni modeli koriste se kako za ispitivanje patogeneze dijabetesa tako i za ispitivanja novih terapijskih sredstava u lečenju šećerne bolesti.

Ključne reči: animalni modeli, eksperimentalni dijabetes, miš, pacov


Received / Primljen: 27. 07. 2010. Accepted / Prihvaćen: 03. 03. 2011.
INTRODUCTION

Since 1880, when von Mering and Minkowski removed the pancreas from a dog displaying symptoms of diabetes mellitus (1), many experiments have been conducted on mice, rats, rabbits, and dogs, which were all used as experimental models for this disease.

The rodents (mice and rats) are most frequently used in laboratory research of type 1 and type 2 diabetes because they are biologically and genetically similar to people, their reproductive potential is high, their life span is short, and they are cheap and easy to handle (1). The main drawback of these models is that sometimes they are unable to successfully simulate pathological processes occurring in humans; in those situations, the use of cats, dogs, pigs or primates is justifiable.

Models of experimental diabetes are:
1. induced (experimental)
2. spontaneous (genetically induced) or
3. transgenic and knock-out models (resulting from genetic engineering).

Hyperglycemia is induced by:
1. surgical method (partial or total pancreatectomy)
2. non-surgical method (using a diabetogenic toxin in experimental animals) (Table 1) (2).

MATERIALS AND METHODS

We searched the electronic databases Medline, Highwire, and Hinari. Selected papers, both original and review, have been summarized and cited with regard to their scientific relevance for this research field.

EXPERIMENTAL MODELS OF TYPE 1 DIABETES MELLITUS

A) Induced models

Multiple low-dose streptozotocin-induced diabetes

Streptozotocin (STZ) is a derivative of nitrosourea that has been isolated from Streptomyces achromogenes. It is a strong alkylating agent that affects glucose transport (the role of glucokinase) and induces numerous lesions in the beta-cell DNA chain (3-5). It can selectively bind to glucose-transport protein 2 (GLUT2), which is predominantly expressed on the membranes of pancreatic beta-cells (3).

Toxicity of the streptozotocin on beta-cells is complex and includes genetic and non-genetic mechanisms (6). Nitric oxide (NO) and other free radicals influenced by streptozotocin result in spontaneous lesions of the DNA chain (7). Damaged DNA chains activate poly-(ADP-ribose) polymerase (PARP) as a reparatory mechanism, which in case of over-activation may have proapoptotic effects (8). PARP knockout mice were shown to be resistant for streptozotocin-induced diabetes (8).

In addition, the toxicity of streptozotocin is associated with a drastic decrease of insulin reserves within beta cells, resulting from the fast catabolism of nicotinamide-adenine-dinucleotide+ (NAD+), a substrate for PARP activation (9). Decrease of NAD+ and ATP+ provokes significant depletion of insulin secretion as well as other basic processes inside the cell. While excessive activation of PARP represents a proapoptotic stimulus, the reduction of necessary cell energy results in cellular necrotic death.

A single high dose of streptozotocin provokes diabetes in rodents, possibly as a result of the direct toxic effect. Multiple low-dose streptozotocin-induced diabetes (when streptozotocin is administered in lower doses (40 mg/kg) during five consecutive days) is an experimental model of type 1 diabetes and immune-mediated insulitis and is widely used for studying the immunological background of this disease (10).

Partial pancreatectomy

The partially pancreatectomised rat was one of the first experimental models of diabetes (11). The surgical removal of 90% of the pancreatic tissue resulted in a slow development of hyperglycemia over the course of 12 weeks to 20 months (12). The period of post-surgical euglycemia is followed by the development of chronic hyperglycemia as a consequence of a further failure of the remaining beta cells.

The first stage of disease refers to glucose intolerance followed by a compensatory hyper-function of beta-cells, the exhaustion of the remaining beta cells and their further breakdown 14 weeks after surgery (12). Altered beta cell gene expression is associated with a decreased production of islet amylin polypeptide (IAPP), transcription factors, ionic canals and pumps, including GLUT2, glucokinase, mitochondrial glycerophosphate dehydrogenase (mGPD) and pyruvate carboxylase (13). A reduction of insulin secretion follows even in conditions of high concentrations of glucose and even after application of insulin secretagogues (14).

Histopathological findings demonstrate hypertrophy and fibrosis of pancreatic islets related to the level of hyperglycemia (13). Insulitis, demonstrated as the infiltration of inflammatory cells, may be depressed, thus slowing down the process of cell degeneration (15).

<p>| Table 1. Toxins with diabetogenic effect |</p>
<table>
<thead>
<tr>
<th>Toxin</th>
<th>Diabetogenic effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptozotocin</td>
<td>Hyperglycemia, glucose intolerance</td>
</tr>
<tr>
<td>Alloxan</td>
<td>Hyperglycemia, glucose intolerance</td>
</tr>
<tr>
<td>Chlorozotocin</td>
<td>Hyperglycemia, glucose intolerance</td>
</tr>
<tr>
<td>Dithizone</td>
<td>Hyperglycemia, glucose intolerance</td>
</tr>
<tr>
<td>Vacor</td>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Oxine</td>
<td>Hyperglycemia</td>
</tr>
<tr>
<td>Methylnitrosurea</td>
<td>Glucose intolerance</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>Glucose intolerance</td>
</tr>
</tbody>
</table>
B) Spontaneous models

The most frequently used spontaneous models of type 1 diabetes are the non-obese diabetic (NOD) mouse and the bio-breeding (BB) rat. These two strains are the result of laboratory inbreeding (keen cross-breeding) of a large number of generations; they develop the disease spontaneously, similar to type 1 human diabetes.

NOD mouse

The NOD mouse is an inbred, homozygous strain discovered in 1974 in Shionogi Research Laboratories in Osaka, Japan. It was a result of keen cross-breeding from normoglycemic strains used for cataract research (Jcl-ICR mouse) and bred in sterile conditions, free from species-specific pathogens (16). The NOD mouse developed insulin detectable by electronic microscopy after 2 weeks, and within 4-5 weeks it becomes visible under standard microscopy (17). The infiltration is mainly characterized by the presence of a large number of CD4+ T lymphocytes, while CD8+ T and B lymphocytes, as well as NK cells are not so numerous (18). Insulitis is progressive and accompanied by the destruction of beta cells and a decrease of insulin levels in serum. In contrast to the disease in the human population, these strains have mild ketoacidosis and can survive for weeks without insulin substitution (1). Incidence of this disease differs between genders (90% among females and 60% among males) (1).

Similar to the human population, the main autoantigens in pathogenesis of this disease, recognized by secreted antibodies, are insulin, glutamic acid decarboxylase (GAD), and tyrosine phosphatase (ICA512, known as IA-2) (19).

The genetic background of diabetes in this model highlights the role of a major histocompatible complex (MHC) class II gene that codes for molecule I-A^d (20-21). The expression of MHC molecule class I refers to proteins K^d and D^d (22). An alteration of INS gene expression, controlling the expression of insulin in the thymus and the deletion of T reactive lymphocytes in the case of central tolerance, is related to an initiation of the autoimmune process (22). A similar situation is observed with the cytotoxic T lymphocyte antigen 4 (CTLA-4) gene, which codes for a negative signal molecule for CD8+ T cells and controls the activation and expansion of T lymphocytes (22). The protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene, associated with autoimmune diabetes, codes for tyrosine phosphatase (LYP or PEP), a negative regulator of T cells (22). Variations of genes coding for IL2 and CD25 FoxP3 that a key role in maintaining immune homeostasis are common for both human and NOD mice (22).

BB rat

The BB rat was discovered in 1974 within the commercial campaign of the Company Bio Breeding Laboratories, Ottawa. It develops diabetes spontaneously (decrease of body weight, polyuria, polydipsia, hyperglycemia and insulopenia) during puberty—approximately the 12th week of life (1). Similar to the human population, the BB rat develops serious/fatal ketoacidosis unless insulin substitution is administered. (1) The disorder is autoimmune, and insulitis is characterized by the infiltration of T lymphocytes, B lymphocytes, macrophages and NK cells (23). Typical for this species is extreme lymphopenia associated with a decreased number of T lymphocytes with an elevated expression of ADP-ribosyltransferase 2 (ART2); this has not been registered in the human population (24). A transfusion of histocompatible T ART2+ lymphocytes prevents spontaneous hyperglycemia in this model (24).

Recent studies show that BB rat diabetic syndrome is a complex, polygenic disease that may share additional susceptibility genes aside from MHC class II with human type 1 diabetes (25). The expression of two main susceptibility genes is responsible for the development of diabetes in the BB rat: MHC (RT1) class II u haplotype (Iddm1) and the Gimap5 (GTPase immunity associated protein family member 5) gene, a key genetic factor for lymphopenia in spontaneous BB rat diabetes (Iddm2) (25).

EXPERIMENTAL MODELS OF TYPE 2 DIABETES

A) Induced models

C57BL/6J mouse fed a high-fat diet

This model was originally introduced by Surwit et al. in 1988 as a robust model of impaired glucose tolerance (IGT) and early type 2 diabetes (26). C57BL/6J mice fed a high-fat diet (58% energy by fat, a "Western diet") developed hyperglycemia, hyperinsulinemia, hyperlipidemia and increased adiposity (27). High-fat diet results in insulin resistance with compensatory hyperinsulinemia. After one week on the diet, baseline plasma glucose and insulin are significantly elevated and intravenous glucose tolerance test (IVGTT) shows reduced glucose elimination and impaired insulin secretion (28). The model thus shows two important pathophysiological characteristics for impaired glucose tolerance (IGT) and type 2 diabetes: insulin resistance and islet dysfunction.

In this model, the weight gain is due primarily to an increase in mesenteric adiposity. In high-fat diet-fed mice, energy intake is higher and metabolic efficiency index is lower compared to normal diet-fed mice (28). Despite obesity, plasma leptin levels are significantly lower than in the control group in the absence of hyperphagia (29). Increased serum lipid levels develop concomitantly with the development of hyperglycemia, thus deteriorating insulin resistance and producing lipid deposits in non-adipose cells, including beta cells and skeletal muscle cells (30). Microscopically, a high-fat diet induces hypertrophy of pancreatic islets (31).

This model is suitable for examining novel therapeutic interventions. The dipeptidyl peptidase-IV (DPP-IV) inhibitor is efficient in improving glucose tolerance and insulin secretion in the high-fat diet-fed mouse model (28).

Partial pancreatectomy as a surgical method of inducing diabetes was described above.
B) Spontaneous models

Goto Kakizaki Rat

The Goto Kakizaki (GK) rat is skinny, diabetic rat developed in Japan in 1975 from Wistar species (6). Both insulin resistance and impaired insulin secretion are present in this model (32). GK rats have a decreased numbers of beta cells at birth, which is probably the consequence of their apoptosis during embryonic development (16-18 days). However, GK rats are still normoglycemic and without marked changes in islet morphology at birth (33). The characteristics of diabetes type 2 in this model are mild hyperglycemia (9 mmol/l) in the fourth week and the increase of basal insulin secretion and insulin resistance followed by a decrease in glucose tolerance (34). GK rats are resistant to food intake restrictions (35).

Starting from the 8th week, insulin islets show signs of fibrosis with a marked elevation of hyperglycemia (36). In addition, the expression of CD38 and GLUT2 proteins is reduced by 40 weeks of age, with greater incidence in males than in females (1). Adult animals are mildly obese and hyperglycemic, with increased appetite and renal glomerulosclerosis. These changes are the result of a deletion of the gene for cholecystokinin 1 receptors. Diet and exercise prevent type 2 diabetes in this model (48).

Histopathologic changes inside the islets during the 8th-10th week show an infiltration of inflammatory cells followed by tissue damage. Beta cell hyperplasia and proliferation occur between the 20th and 40th weeks, while atrophy and fibrosis of the islets start after the 40th week (47). From the 72nd week, inflammatory cytokines (tumour necrosis factor- (TNF-), interleukin-1β (IL-1β) and interleukin-6 (IL-6)) are detectable by immunohistochemical method (49).

Psammomys obesus

The Psammomys obesus is rat from North America and the Middle East. It usually feeds on a low-calorie diet and demonstrates the strong effect of a high-calorie diet by developing hyperglycemia within 4-7 days (6).

Pathogenesis of the disorders goes through four typical stages: normoglycemia and normoinsulinemia, normoglycemia with hyperinsulinemia (indicating insulin resistance), hyperglycemia with hyperinsulinemia, and hyperglycemia with hypoinsulinemia (50). The last stage is characterized by marked apoptosis and a reduction of beta cell mass (51). Returning to a low-calorie diet results in the recovery of beta cells, indicating that the irreversible loss of beta cell mass is a late event (52).

TRANSGENIC AND KNOCKOUT MODELS OF DIABETES MELLITUS

In experimental diabetes, numerous transgenic and knockout models are being used. These models have been created by genetic manipulations using either transgene insertion and/or targeted gene-deletion approaches.

Still, these techniques have some limitations. Some homozygotes may die in the womb, which makes studies in adults impossible. Several genes could function differently during embryogenesis and in adulthood. Finally, some models’ gene expression is altered in soft tissues, and therefore it is impossible to analyze their function in the desired tissue. Tissue-specific knockout models for diabetes, in which the gene being studied is only knocked out in specific tissues, were created to address this issue.
REFERENCES


The first knockout models of insulin resistance aimed at the disruption of major molecules in insulin receptor (IR) signaling. Heterozygous IR knockout mice show 50% of IR expression, which is sufficient for the maintenance of physiological blood glucose concentrations (53). In contrast, homozygous IR-deficient mice rapidly develop diabetic ketoacidosis and die within 3-7 days after birth, showing the central role of IR in glucose metabolism (54). Aside from IR knockouts, various molecules of the signal transduction pathway initiated by IR have been disrupted, such as insulin receptor substrates (IRS-1, IRS-2, IRS-3) (55-58). Insulin resistance and insulin secretory defects have also been presented by a generation of mice deficient in beta cell glucokinase (GK). The heterozygous beta cell GK knockout mouse is characterised by decreased insulin secretion in response to glucose (59). The homozygous knockout mouse model with a disrupted gene for the glucose transporter 4 (GLUT4), which mediates glucose transport in muscle and adipose tissue in response to insulin, is characterised by mild changes in glucose hemostasis, growth retardation, reduction of fat and cardiac hypertrophy (60). The important physiological role of peroxisome proliferator-activator receptors (PPARα and PPARγ) was deduced from findings identifying the PPARs as primary targets of tiasolidinedione insulin sensitizers and fibrates that have been used in the successful treatment of diabetes and dyslipidemia. Diverse knockout models have been created to study the function of single PPARs isoforms (61-63). Similar to other mouse models, a transgenic human islet amyloid polypeptide-expressing rat has been recently developed (64). This model shows pancreatic amyloidosis, insulin resistance, and reduced β-cell mass with resulting hyperglycemia (64). Some of the transgenic/knockout and tissue-specific knockout models are presented in Table 2.

<table>
<thead>
<tr>
<th>Mouse/rat model</th>
<th>Phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>IR +/-</td>
<td>Mild insulin resistance</td>
<td>53, 54</td>
</tr>
<tr>
<td>IR -/-</td>
<td>Severe hyperglycemia, neonatal death from ketoacidosis</td>
<td>54</td>
</tr>
<tr>
<td>IRS-1 -/-</td>
<td>Mild insulin resistance, normoglycemia, elevated serum triglycerides, hypertension, growth retardation</td>
<td>55</td>
</tr>
<tr>
<td>IRS-2 -/-</td>
<td>Insulin resistance, hyperglycemia, reduced beta-cell mass</td>
<td>56</td>
</tr>
<tr>
<td>IRS-1 -/- IRS-3 -/-</td>
<td>Hyperglycemia, lipatrophy, decreased plasma levels of leptin, hyperinsulinemia</td>
<td>57</td>
</tr>
<tr>
<td>IRS-1 +/- IR +/-</td>
<td>Insulin resistance, beta-cell hyperplasia</td>
<td>58</td>
</tr>
<tr>
<td>GK -/-</td>
<td>Hyperglycemia, perinatal death</td>
<td>59</td>
</tr>
<tr>
<td>GK +/-</td>
<td>Glucose intolerance</td>
<td>59</td>
</tr>
<tr>
<td>GLUT4 +/-</td>
<td>Mild changes in glucose hemostasis, growth retardation, reduction of fat, cardiac hypertrophy</td>
<td>60</td>
</tr>
<tr>
<td>PPARγ +/-</td>
<td>Mild insulin resistance</td>
<td>61</td>
</tr>
<tr>
<td>PPARγ2 +/-</td>
<td>Insulin resistance, reduction of white adipose tissue</td>
<td>62</td>
</tr>
<tr>
<td>PPARα +/-</td>
<td>No phenotypical defect without pharmacological intervention</td>
<td>63</td>
</tr>
<tr>
<td>hIAPP +/- rat</td>
<td>Decreased proliferation and increased apoptosis of beta cell, hyaline replacement of islet cells</td>
<td>64</td>
</tr>
</tbody>
</table>

Table 2. Transgenic and knockout models of Diabetes mellitus


